Biopharmaceuticals
Oncology
Drug Delivery
News Release - July 26, 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.